Pfizer Will Re-Brand Viagra As Revatio For Pulmonary Arterial Hypertension
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer submits sildenafil for pulmonary arterial hypertension under Revatio trademark; firm also plans to differentiate the PAH indication from the Viagra brand with different color and shape tablets. Pfizer is requesting priority review for the NDA, submitted Dec. 2
You may also be interested in...
Year-End 2004 Submissions Slow; FDA Returns To Boom In Approvals
Year-end submissions are down, but end-of-year approvals are up at 15 versus six in 2003. December 2004 saw 14 filings compared to 17 a year ago. Submission slow-down reflects diminishing late-stage pipelines across industry; only five of the end-of-year filings were for new molecular entities
Year-End 2004 Submissions Slow; FDA Returns To Boom In Approvals
Year-end submissions are down, but end-of-year approvals are up at 15 versus six in 2003. December 2004 saw 14 filings compared to 17 a year ago. Submission slow-down reflects diminishing late-stage pipelines across industry; only five of the end-of-year filings were for new molecular entities
Pharmacia New Parecoxib Studies Will Begin Shortly; U.K. Launch Underway
Pharmacia will soon initiate three FDA-requested trials of parecoxib in order to resubmit its NDA within 12 to 18 months, according to the company.